Olanzapine and Kenalog drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Olanzapine (olanzapine) and Kenalog (triamcinolone acetonide). Common drug interactions include drug ineffective among females and appetite disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Olanzapine and Kenalog. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 69,242 Olanzapine users. Check the latest studies of Olanzapine.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

On Jul, 15, 2026

17 people who take Olanzapine and Kenalog together, and have interactions are studied.

Olanzapine and Kenalog drug interactions.

What are the common drug interactions of Olanzapine and Kenalog, by gender? *:

female:

Drug ineffective
Drug level increased
Electrocardiogram qt prolonged
Macular degeneration (painless eye condition that leads to the gradual loss of central vision)
Schizoaffective disorder (a mental disorder characterized by disordered thought)
Mucosal inflammation (infection of mucous membrane)
Adverse drug reaction
Anxiety
Blood pressure decreased
Blood pressure increased

male:

Appetite disorder (abnormal eating habits)
Dysgeusia (disorder of the sense of taste)
Nausea (feeling of having an urge to vomit)
Neuropathy peripheral (surface nerve damage)
Platelet count decreased
Conjunctivitis (pink eye)
Muscular weakness (muscle weakness)
Ageusia (loss of taste functions of the tongue)
Decreased appetite
Malaise (a feeling of general discomfort or uneasiness)

What are the common drug interactions of Olanzapine and Kenalog, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Appetite disorder (abnormal eating habits)
Dysgeusia (disorder of the sense of taste)
Nausea (feeling of having an urge to vomit)
Neuropathy peripheral (surface nerve damage)
Platelet count decreased
Mucosal inflammation (infection of mucous membrane)
Ageusia (loss of taste functions of the tongue)
Decreased appetite
Malaise (a feeling of general discomfort or uneasiness)

40-49:

n/a

50-59:

Adverse drug reaction
Anxiety
Blood pressure decreased
Blood pressure increased
Chest pain
Dyspnoea (difficult or laboured respiration)
Nightmare (unpleasant dream)
Oedema peripheral (superficial swelling)
Sedation

60+:

Conjunctivitis (pink eye)
Muscular weakness (muscle weakness)
Osteomyelitis (infection of bone)
Confusional state
Death
Fall
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Haematemesis (vomiting of blood)
Laceration (tearing of soft body tissue)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)

What are the existing conditions these people have? *

Fever: 7 people, 41.18%
Insomnia (sleeplessness): 7 people, 41.18%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 6 people, 35.29%
Abdominal Discomfort: 5 people, 29.41%
Allergies: 5 people, 29.41%
Rashes (redness): 5 people, 29.41%
Mood Swings (an extreme or rapid change in mood): 5 people, 29.41%
Constipation: 4 people, 23.53%
Nausea (feeling of having an urge to vomit): 4 people, 23.53%
Multiple Myeloma (cancer of the plasma cells): 4 people, 23.53%

* Approximation only. Some reports may have incomplete information.

Do you take Olanzapine and Kenalog?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously